UIDP Webinar Recording: Bespoke Gene Therapy Consortium: Opportunities for Engagement
In October 2021, the Foundation for the National Institutes of Health announced the launch of the Bespoke Gene Therapy Consortium (BGTC), the seventh program under the Accelerating Medicines Partnership® (AMP) since its launch in 2014. The BGTC is the largest AMP program to date and the first focused on a therapeutic platform rather than a specific disease or disease area. The effort brings together the National Institutes of Health, the U.S. Food and Drug Administration, multiple pharmaceutical and biotech companies, and non-profit patient advocacy groups to advance manufacturing and regulatory frameworks for adeno-associated virus (AAV) gene therapies. The webinar discussed the structure and goals of the BGTC, ways that organizations can participate, and research and clinical program opportunities that are currently available.
Wednesday, January 19, 2022
- Courtney Silverthorn, Associate Vice President, Research Partnerships Foundation for the National Institutes of Health
- JoonHyung Cho, Director of Corporate Relations and Business Development, The University of Virginia